652 reports of this reaction
3.5% of all AMLODIPINE BESYLATE AND VALSARTAN reports
#1 most reported adverse reaction
BLOOD PRESSURE INCREASED is the #1 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 652 FDA adverse event reports linking AMLODIPINE BESYLATE AND VALSARTAN to BLOOD PRESSURE INCREASED. This represents approximately 3.5% of all 18,550 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND VALSARTAN who experience blood pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD PRESSURE INCREASED is moderately reported among AMLODIPINE BESYLATE AND VALSARTAN users, representing a notable but not dominant share of adverse events.
In addition to blood pressure increased, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND VALSARTAN:
The following drugs have also been linked to blood pressure increased in FDA adverse event reports:
BLOOD PRESSURE INCREASED has been reported as an adverse event in 652 FDA reports for AMLODIPINE BESYLATE AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD PRESSURE INCREASED accounts for approximately 3.5% of all adverse event reports for AMLODIPINE BESYLATE AND VALSARTAN, making it one of the most commonly reported side effect.
If you experience blood pressure increased while taking AMLODIPINE BESYLATE AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.